Enliven Therapeutics (ELVN) Return on Capital Employed (2020 - 2026)
Enliven Therapeutics (ELVN) reported Return on Capital Employed of 25.22% for Q1 2026, up 1150.0% on a YoY basis from 2.02% in Q1 2025, and up 1.56% sequentially from 25.63% in Q4 2025.
Enliven Therapeutics (ELVN) Return on Capital Employed (2020 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 7 years of Return on Capital Employed data on file, last reported at 25.22% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1150.0% year-over-year to 25.22%; the trailing twelve-month figure through Mar 2026 stood at 25.22% (up 1150.0% YoY), and the FY2025 full-year result was 31.13%, up 583.0% from the prior year.
- Return on Capital Employed climbed to 25.22% in Q1 2026, from 25.63% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 20.12% in Q2 2023 to a low of 71.52% in Q3 2022.
- A 5-year average of 37.69% and a median of 32.98% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed plunged 1259 bps in 2022 and soared 4530 bps in 2023, its largest moves.
- Tracing ELVN's Return on Capital Employed over 5 years: stood at 63.09% in 2022, then surged by 46 bps to 33.81% in 2023, then decreased by 3 bps to 34.89% in 2024, then advanced by 27 bps to 25.63% in 2025, then increased by 2 bps to 25.22% in 2026.
- Business Quant data shows ELVN's Return on Capital Employed at 25.22% in Q1 2026, 25.63% in Q4 2025, and 23.26% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | -25.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.22% |
| Dec 31, 2025 | -25.63% |
| Sep 30, 2025 | -23.26% |
| Jun 30, 2025 | -29.44% |
| Mar 31, 2025 | -36.73% |
| Dec 31, 2024 | -34.89% |
| Sep 30, 2024 | -33.55% |
| Jun 30, 2024 | -31.19% |
| Mar 31, 2024 | -32.98% |
| Dec 31, 2023 | -33.81% |
| Sep 30, 2023 | -26.36% |
| Jun 30, 2023 | -20.12% |
| Mar 31, 2023 | -25.55% |
| Dec 31, 2022 | -63.09% |
| Sep 30, 2022 | -71.52% |
| Jun 30, 2022 | -65.42% |
| Mar 31, 2022 | -61.99% |
| Dec 31, 2021 | -55.24% |
| Sep 30, 2021 | -58.94% |
| Jun 30, 2021 | -67.75% |